Alnylam Pharmaceuticals Inc

Common Name
Alnylam Pharmaceuticals
Country
United States
Sector
Healthcare
Industry
Biotechnology
Employees
2,230
Ticker
ALNY
Exchange
NASDAQ/NGS
Description
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for inn...

Alnylam Pharmaceuticals Waste Data Preview

In 2023, Alnylam Pharmaceuticals conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards. The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.

Metric (tonnes)2023202220212020 - 2017
Total Waste Generated
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Waste Recovered
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Hazardous Waste Generated
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Non-Hazardous Waste Disposed
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Download Alnylam Pharmaceuticals's Waste Management data for free

Create your Tracenable account today and download up to 5 company datasets of your choice for free. No credit card required.

Verified Sources Behind Alnylam Pharmaceuticals’s Waste Management Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Alnylam Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.

a. Alnylam Pharmaceuticals's Corporate Responsibility Report (CRR) 2023
Trace every data point back to Alnylam Pharmaceuticals’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Insights into Alnylam Pharmaceuticals's Waste Treatment Practices

In 2023, Alnylam Pharmaceuticals generated a total of 954 metric tonnes of waste. a

Of this amount, 7.86% of Alnylam Pharmaceuticals's total waste generated was recovered through methods such as recycling, reuse, or composting, while 92.14% was disposed of through landfilling, incineration, or combustion. a

Alnylam Pharmaceuticals's Waste Recovery Rate

8%

How much of Alnylam Pharmaceuticals's waste is recycled or recovered?

In 2023, Alnylam Pharmaceuticals reported a total waste generation of 954 metric tonnes, of which 7.86% was recovered through recycling, reuse, or composting. This low recovery rate highlights limited waste diversion and suggests that Alnylam Pharmaceuticals may be relying more heavily on landfill or incineration, underscoring opportunities for stronger resource recovery initiatives. a

Has Alnylam Pharmaceuticals reduced its environmental waste footprint over time?

Since 2021, Alnylam Pharmaceuticals's total waste generation increased by 13.98%, including a 72.51% increase in 2023, indicating a persistent upward trend that may reflect scaling operations, inefficiencies in resource use, or a lack of effective waste minimization practices. a

Over the same period, Alnylam Pharmaceuticals's waste recovery rate declined by 68.52%, with a further 42.03% drop in 2023, underscoring a weakening in waste diversion performance and a potential drift away from circular waste strategies. a

Overall, Alnylam Pharmaceuticals is generating more waste while simultaneously backsliding on recovery efforts, both in the short and long term. This dual negative trend raises concerns about the company’s waste management priorities and its alignment with sustainability goals.

Alnylam Pharmaceuticals’s Waste Recovery vs. Disposal Over Time

20212022202302505007501 ktonnes
  • Total Waste Disposed
  • Total Waste Recovered

Insights into Alnylam Pharmaceuticals’s Generation of Hazardous and Non-Hazardous Waste

In 2023, Alnylam Pharmaceuticals generated a total of 954 metric tonnes of waste. a

Of this amount, 57.23% of Alnylam Pharmaceuticals's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment. 42.56% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls. a

Alnylam Pharmaceuticals’s Hazardous vs Non-Hazardous Waste Over Time

20212022202302505007501 ktonnes
  • Total Non-Hazardous Waste Generated
  • Total Hazardous Waste Generated

How Alnylam Pharmaceuticals reduced the environmental impact of its waste?

Since 2021, Alnylam Pharmaceuticals's total waste generation increased by 13.98%, including a 72.51% rise in 2023, reflecting a persistent upward trend that could be linked to operational growth, inefficient material use, or limited investment in waste prevention systems. a

Over the same period, the share of hazardous waste in Alnylam Pharmaceuticals's total output increased by 8.38%, including a further 12.63% rise in 2023, suggesting a troubling upward shift toward more environmentally harmful waste streams that could raise compliance costs and environmental risks. a

Overall, Alnylam Pharmaceuticals has seen a continuous rise in both total waste and hazardous waste over time, signaling a worsening environmental impact that may require urgent reassessment of material sourcing, production processes, or waste mitigation strategies. a

How does Alnylam Pharmaceuticals treat its hazardous waste?

In 2023, Alnylam Pharmaceuticals reported that 546 metric tonnes of its total waste output were classified as hazardous. This represents 57.23% of its overall waste generation. a

The company treated this hazardous waste using a combination of methods. Only 0.92% of hazardous waste was recovered, meaning the vast majority was treated through disposal methods such as landfilling or incineration. This raises concerns about the environmental and health risks associated with Alnylam Pharmaceuticals’s current hazardous waste practices. a

Breakdown of Alnylam Pharmaceuticals's Hazardous and Non-Hazardous Waste by Treatment Method

Hazardous WasteDisposed(56.8%)Non-Hazardous WasteDisposed(35.3%)Non-Hazardous WasteRecovered(7.4%)
Want Full Access to Alnylam Pharmaceuticals's Waste Management Dataset?
Sign Up